Insilico Medicine

Primary contact

Insilico Medicine dubs itself the next-generation artificial intelligence company that utilizes advances in genomics, big data analysis and deep learning for in-silico drug discovery and biomarker development for age-related diseases. The company pursues internal drug discovery programs in cancer, Parkinson's, Alzheimer's, ALS, metabolic diseases, sarcopenia, and geroprotector discovery. Through its Pharma.AI division, Insilico provides advanced machine learning services to biotechnology, pharmaceutical, and skin care companies. The company's other projects include Aging.AI 2.0, Embryonic.AI, Nutriomi, and Mortality.AI (coming soon). Insilico licenses hundreds of drug-disease predictions and biomarkers, including antineoplastic agents, metabolic regulators, CVD disease candidates, CNS agents, anti-cancer immune response boosters, senolytics, aging and cancer biomarkers (biochemical and transcriptional).
Primary contact

Funding 💰

Total $14M
Select investors Deep Knowledge Ventures, A-Level Capital, SoGal Ventures
Last update: April 24, 2018